Procedures
Preeclampsia, seizure
PREECLAMPSIA
Once the center had transitioned to implement the intervention, all patients had sFlt-1/PlGF ratio measurement and fullPIERS assessment performed as part of their routine care, and results were revealed to the clinicians. sFlt-1 and PlGF were measured using the Elecsys Preeclampsia Platform (Roche Diagnostics) and the results were entered into a trial-specific Global Pregnancy Collaboration database.If sFlt-1/PlGF ≤38 and fullPIERS <10% risk, patients were considered low risk. The output provided by the platform was: reassuring—low risk for adverse outcomes. The recommendations were that delivery should be delayed unless the clinical condition deteriorated, with testing repeated at least twice weekly with fullPIERS and at least weekly with sFlt-1/PlGF for reassessment,If sFlt-1/PlGF>38 and fullPIERS ≥10% risk, patients were considered not low risk. The output provided by the platform was: nonreassuring—high risk for adverse outcomes, with recommendations to increase surveillance based on the World Health Organization guideline for management and delivery, including the need for preventative therapy with antihypertensive therapy, magnesium sulfate for seizure prophylaxis, and corticosteroids for fetal benefits.